Avutometinib potassium is under clinical development by Verastem and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Avutometinib potassium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Avutometinib potassium overview

Avutometinib potassium (RG-7304, RO5126766) is under development for the treatment of solid tumors including low-grade serous ovarian cancer (LGSOC) , peritoneal cancer, metastatic uveal melanoma, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, non-small cell lung cancer, multiple myeloma, endometrial cancer, prostate cancer, cervical cancer, HER2 negative breast cancer and colorectal cancer. It is administered orally as a capsule. It is a new molecular entity (NME) with a structure based on a coumarin skeleton. The drug candidate acts by targeting B-Raf kinase, C-Raf kinase, mitogen activated protein kinase kinase 1 (MEK-1 or MAP2K1). It was also under development for melanoma, pancreatic cancer and solid tumors in Japan.

Verastem overview

Verastem is a biopharmaceutical company. It carries out the discovery, development, and commercialization of novel small molecule drugs to treat cancer. The company’s most advanced product candidates include VS-6766, defactinib (VS-6063). Verastem products VS-6766 and defactinib (VS-6063), are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. The pipeline products focused on RAF/MEK inhibition and FAK inhibition. Its service include investigator sponsored trial (IST)program. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.

For a complete picture of Avutometinib potassium’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.